Pharm.D vs MBBS

Image by Cool Text: Free Graphics Generator - Edit Image

Hi!Friends

PharmD vs MBBS which one would be better......?

Which one would be more rewarding,doing plain MBBS or Pharm.D(Doctorate of Pharmacy).By plain MBBS I mean doing MBBS without thinking about any post graduation or specialization i.e being an MBBS doctor and not more.I'm laying down the course structure and scope of both Pharm D and MBBS so that it can be much more clear.

Syllabus of Pharm-D course conducted by Rajiv Gandhi University

First Year
1.1 HUMAN ANATOMY & PHYSIOLOGY
1.3 MEDICINAL BIOCHEMISTRY
BIOLOGY/ MATHS:
Second year
2.1 PATHOPHYSIOLOGY
2.2 PHARMACEUTICAL MICROBIOLOGY
2.4 PHARMACOLOGY – I
2.5 COMMUNITY PHARMACY( very important)
2.6 PHARMACOTHERAPEUTICS – I
Third year
3.1 PHARMACOLOGY – II
3.3 PHARMACOTHERAPEUTICS – II
3.4 PHARMACEUTICAL JURISPRUDENCE
Fourth year
4.1 PHARMACOTHERAPEUTICS – III
4.2 HOSPITAL PHARMACY
4.3 CLINICAL PHARMACY
4.6 CLINICAL TOXICOLOGY
Fifth year
5.1 Clinical Research
5.2 Pharmacoepidemiology and
Pharmacoeconomics
5.3 Clinical Pharmacokinetics &
Pharmacotherapeutic Drug Monitoring
5.4 Clerkship
Sixth Year:
Internship or residency training including postings in speciality units. Student should independently provide the clinical pharmacy services to the allotted wards.
(i) Six months in General Medicine department, and
(ii) Two months each in three other speciality departments
Internship._ (1) Internship is a phase of training wherein a student is expected to conduct actual practice of pharmacy and health care and acquires skills under the supervision so that he or she may become capable of functioning independently.
The following are the expected role of a pharmacist in the future health sector which given by IPA:
Some of the roles of PharmD (community) pharmacists are as follows:
1. Patient medication history interview
2. Medication order review
3. Patient counseling regarding safe and rational use of drug
4. Adverse drug reaction monitoring
5. Drug interaction monitoring
6. Therapeutic drug monitoring
7. Participating in ward rounds
8. Providing drug information at the drug information and poison information centre.

Career options available to PharmD Graduates:
 1. Community Pharmacy
 2. Hospital Pharmacy
 3. Pharmaceutical Industry
 4. Pharmacy Education
 5. Bio-medical research
 6. Community Pharmacy
 7. Hospital Pharmacy
 8. Pharmaceutical Industry
 9. Pharmacy Education
 10 .Bio-medical research
 11. Geriatric Pharmacy
 12. Governmental Agencies
 13. Home Healthcare
 14. General Practice in Modern Medicines
 15. Insurance sector
 16. Health care documentation (like archivers)

MBBS syllabus
Proposed MBBS curriculum by MCI.Structure and Duration of the Course
The committee recommends the following for consideration for implementation:
4.5 years course + 1 year internship).The course would be of 5.5 years duration with one year internship and provision for elective periods of 6 months before or after internship. Curriculum can be divided into core and non-core with the non-core part of the curriculum be made elective or applied.

Subject covered
Group A:
Year1-
Anatomy,
Physiology and Biochemistry;
Year 2-
Pathology,
Microbiology and Pharmacology
Group B:
Year 4-
Medicine,
Surgery
Obstetrics and Gyanecology,
Paediatrics,
Family Medicine and Community health
Group C :
Year 2-
Forensic medicine
Year 3 and 4-
ENT and Opthalmology,
STD and Dermatology,
Orthopaedics,
Accident and Emergency Medicine,
Radiology,
Anaesthesia,
Psychiatry
Elective options- clinical and research electives
.
Career options available to MBBS Graduates:
1. General Practice
2. Govt/Public sector/Private sector
3.Academics
4. Health care documentation
5. Health care management
6. Insurance sector

·         

Additional Details

The Pharm-D syllabus as laid down by Pharmacy council of India have covers almost all of the diseases through various subjects and the corresponding practical via different names and heads. It is not like that of MBBS curriculum where the sections are categorized as general medicine, paediatrics, ENT, etc. But here they have interpreted everything in a different way.One cannot make out clearly, at first sight; to what extent the student is taught about general medicine and the clinical aspects but intact Pharm D and MBBS are same in regards to general medicine and the clinical aspects.

As pharm D is a doctoral degree any body graduating as Pharm D can put 'Dr' as prefix in front of his name.

5 YEAR ROADMAP OF PHARMACOVIGILANCE PROGRAMME OF INDIA (Year 2010—2015 )

Hi!Friends  

Presented below is the roadmap for the Pharmacovigilance Programme of India. The programme will be implemented in five phases as depicted below:

Introduction  

The Pharmaceutical industry in India is valued at Rs. 90,000 Crore and is growing at the rate of 12 – 14 % per annum. Exports are growing at 25 % Compound Annual Growth Rate (CAGR) every year. The total export of Pharma products is to the extent of Rs. 40,000 Crore. India is now being recognized as the ‘Global pharmacy of Generic Drugs’ & has distinction of providing generic quality drugs at affordable cost. India is also emerging rapidly as a hub of Global Clinical trials & a destination for Drug Discovery & Development.

Further, more & more  new drugs are being introduced into the country which include New Chemical Entities (NCE), high techpharma products, vaccines  as well as new dosage forms, new routes of drug administrations and new therapeutic claims of existing drugs. This is reflected in the fact that total number of applications received & processed have more than doubled from around 10,000 in the Year 2005 to 22,806 in Year 2009 at CDSCO, HQ, New Delhi. This includes increase in New Drug Applications, Global Clinical Trials, Market Authorization of Vaccine & Biotech products from 1200 ,100 ,10 in Year 2005 to 1753, 262 & 137 in the Year 2009 respectively. 

 Such rapid induction of NCEs and High tech Pharma products in the market throw up the challenges of monitoring Adverse Drug Reactions (ADRs) over large population base.All medicines (pharmaceuticals and vaccines) have side effects. Some of these side effects are known, while many are still unknown even though that medicine has been in clinical use for several years. It is important to monitor both the known and hitherto unknown side effects of medicines in order to determine any new information available in relation to their safety profile. In a vast country like India with a population of over 1.2 Billion with vast ethnic variability, different disease prevalence patterns, practice of different systems of medicines, different socioeconomic status, it is important to have a standardized and robust pharmacovigilance and drug safety monitoringprogramme for the nation.  Collecting this information in a systematic manner and analyzing the data to reach a meaningful conclusion on the continued use of these medicines is the rationale to institute this program for India.

Since, there are considerable social and economic consequences of ADRs there is a need to engage health-care professionals, in a well structured programme to build synergies for monitoring ADRs. The purpose of the Pharmacovigilance Program of India is to collect, collate and analyze data to arrive at an inference to recommend regulatory interventions, besides communicating risks to healthcare professionals and the public

2.            Pharmacovigilance Programme of India (PvPI)

 The Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services under the aegis of Ministry of Health & Family Welfare, Government of India in collaboration with Indian Pharmacopeia commission, Ghaziabad is initiating a nation-wide Pharmacovigilance programme for protecting the health of the patients by assuring drug safety. The programmeshall be coordinated by the Indian Pharmacopeia commission, Ghaziabad as a National Coordinating Centre (NCC). The centre will operate under the supervision of a Steering Committee.

http://www.cdsco.nic.in/pharmacovigilance.htm

Pharmacovigilance Programme of India (PvPI) for Assuring Drug Safety

Plan to develop Pharmacovigilance in INDIA

PHARMACOVIGILANCE PROGRAMME OF INDIA

TRAININGS/EVENTS CALENDER 2013

Objectives	Activities planned	Begin /End or Duration	Institution responsible to follow up	Remarks
Strengthening of Pharmacovigilance Programme of India	PvPI Working Group Meeting  at FDA Bhawan, New Delhi	29th January 2013	IP Commission, Ghaziabad	IPC Budget
	Workshop on ADR Monitoring and Reporting at ALT Centre, Ghaziabad	9th and 10th February 2013	Vardhman Foundation	IPC will provide technical support
	Vigiflow training for North Zone ADR Monitoring Centres at PGIMER, Chandigarh	February 2013	NorthZone Training &Tech Support Centre Coordinator	IPC Budget
	Pharmacovigilance training for East zone ADR Monitoring Centres at IPGMER, Kolkata	February 2013	East Zone Training & Tech Support Centre Coordinator	IPC Budget
	Vigiflow training for West Zone ADR Monitoring Centre at KEM Hospital, Mumbai	March 2013	West Zone Training & Tech Support  Centre Coordinator	IPC Budget
	Vigiflow training for South Zone ADR Monitoring Centres at  JSS College and Hospital, Mysore	April 2013	South Zone Training & Tech Support Centre Coordinator	IPC Budget
	PvPI Working Group Meeting  at FDA Bhawan, New Delhi	7th May 2013	IP Commission,  Ghaziabad	IPC Budget
	Vigiflow training for East Zone ADR Monitoring Centres at IPGMER, Kolkata	May 2013	East Zone Training & Tech Support Centre Coordinator	IPC Budget
	Workshop on Quality Management System in Pharmacovigilance at IP Commission,  Ghaziabad	July 2013	IP Commission, Ghaziabad	IPC Budget
	PvPI Working Group Meeting at FDA Bhawan, New Delhi	10th September 2013	IP Commission, Ghaziabad	IPC Budget

.

Quick Link : http://www.cdsco.nic.in/pharmacovigilance.htm